Harbour BioMed
Dr. Xiaolu Tao, is the Chief Development Officer. Prior to joining Harbour BioMed, Dr. Tao served as Head of Clinical Pharmacology & Bioassay at Cstone. Before moving back to China, Dr. Tao worked at BMS as Clinical Pharmacology Director in the therapeutic areas of immunology and oncology for multiple innovative products.
This person is not in any teams
This person is not in any offices
Harbour BioMed
1 followers
Harbour BioMed is an Immune-Driven Global Bio-therapeutics Company discovering, developing and delivering Innovative Therapeutics for Oncology and Immunology. The company's discovery and development programs are centered around its two patented transgenic mouse platforms for human antibody discovery - the H2L2 and the HCAb.